6,564 results match your criteria: "Hypereosinophilic Syndrome"
The effect of benralizumab on inflammation in severe asthma: a real-life analysis.
Ther Adv Respir Dis
December 2024
Department of Medicine and Surgery, University of Insubria, Varese, Italy.
Background: Benralizumab is a monoclonal antibody treatment for severe eosinophilic asthma (SEA). Few studies investigated its role in airway inflammation and its correlation with lung function.
Objectives: The aim of the present study is to assess its effect after 1 year of treatment, focusing on airway inflammation.
Fulminant eosinophilic myocarditis and refractory ventricular arrhythmias requiring mechanical circulatory support: a case report.
Eur Heart J Case Rep
October 2024
Baker Heart and Diabetes Institute, Melbourne, Victoria 3004, Australia.
Background: Fulminant eosinophilic myocarditis (EM) is a rare and often fatal condition that may present atypically and be complicated by ventricular arrhythmias. Treatment involves high-dose corticosteroids to suppress eosinophilia, as well as increasing use of mepolizumab, an anti-interleukin-5 antibody with evidence for long-term efficacy and safety.
Case Summary: A 38-year-old woman presented to the emergency department with neck pain and fatigue, and after extensive investigation was diagnosed with EM secondary to idiopathic hypereosinophilic syndrome.
Hyper eosinophilic diseases - diagnosis and therapeutic approach - practical position of the Polish working group.
Otolaryngol Pol
December 2024
Department of Internal Medicine, Asthma and Allergy, Medical University of Lodz, Poland.
Hypereosinophilic diseases represent a heterogeneous group that poses a significant medical challenge. An increased number of eosinophils in the blood can be a dominant symptom of hematologic diseases, such as myeloid hematopoietic cancers or lymphomas. However, it is more commonly associated with other health conditions, such as allergies, infections, and systemic inflammatory diseases.
View Article and Find Full Text PDFCardiac Abnormalities in Hypereosinophilic Syndromes.
Arq Bras Cardiol
October 2024
Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP - Brasil.
Article Synopsis
- Hypereosinophilia (HE) is characterized by an eosinophil count over 1500 cells/microL in blood tests, confirmed by either blood tests or high eosinophil percentages in bone marrow samples. Hypereosinophilic syndrome (HES) involves organ damage due to eosinophils and can be classified as primary, secondary, or idiopathic.
- Cardiac issues occur in 5% of acute cases and 20% of chronic cases of HES, presenting symptoms like heart failure and arrhythmias, but the severity of heart problems isn't always proportional to eosinophil levels.
- Diagnosis of cardiac involvement relies on advanced imaging techniques, particularly
Chronic eosinophilic leukaemia-Not otherwise specified: Clinical features, genomic insight and therapeutic strategies.
Br J Haematol
November 2024
Hematology, Department of Translational and Precision Medicine, Az. Policlinico Umberto I-Sapienza University, Rome, Italy.
Article Synopsis
- * Recent genetic research has led to better classification of some CEL subtypes that have specific genetic markers, potentially opening up options for targeted therapies, but CEL-NOS lacks these markers.
- * The overall prognosis for CEL-NOS is poor, especially after transplantation, where only about one-third of patients survive five years, and current treatment methods offer limited benefits and significant side effects, highlighting the need for future research.
Eosinophilic Pneumonia Triggered by in a Patient with Primary Ciliary Dyskinesia: A Clinical Case Report.
Medicina (Kaunas)
November 2024
Department of Nucleic Acid Biochemistry, Medical University of Lodz, 92-213 Lodz, Poland.
Article Synopsis
A Storm of Polyserositis: Unravelling Multisystem Effusions in Hypereosinophilic Syndrome.
Cureus
November 2024
Respiratory Medicine, Dartford and Gravesham NHS Trust, Dartford, GBR.
Article Synopsis
- Idiopathic hypereosinophilic syndrome (i-HES) is a rare condition marked by high eosinophil levels and organ damage without a clear cause.
- A 42-year-old man with no prior health issues showed symptoms similar to pneumonia but worsened to serious complications despite antibiotics, leading to the diagnosis of i-HES after ruling out other causes.
- Quick treatment with high-dose corticosteroids significantly improved his condition, highlighting the need for early detection and comprehensive care in managing i-HES's severe manifestations.
Management of multiple valve replacement operations for a young patient with hypereosinophilic syndrome and valvular heart disease: a case report.
Gen Thorac Cardiovasc Surg Cases
November 2024
Department of Cardiovascular Surgery, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Article Synopsis
- * The patient had issues with his artificial aortic valve leading to severe stenosis, while his prosthetic mitral valve showed mild problems, prompting the fifth surgery to replace the aortic valve with a new bioprosthetic valve.
- * The report emphasizes the importance of managing eosinophil levels before and after surgery, alongside careful selection of artificial valves, to enhance treatment outcomes for patients with HES and related heart valve diseases.
Unexpected Multiple Gastrointestinal Cancers in a Patient with Chronic Eosinophilia: A Case Report.
J Gastrointest Cancer
November 2024
Department of Surgery, Second Affiliated Hospital of School of Medicine, Zhejiang University, Hangzhou City, People's Republic of China.
Purpose: While the relationship between eosinophilia and tumors has been extensively studied, eosinophilia is primarily observed clinically after tumor development, with no prior reports of eosinophilia occurring before tumor onset. This case report presents a unique instance of eosinophilia preceding the development of gastric cancer in an old male patient.
Methods: The patient was evaluated after being diagnosed with gastric cancer.
Dupilumab Use in Patients With Hypereosinophilic Syndromes: A Multicenter Case Series and Review of the Literature.
J Allergy Clin Immunol Pract
November 2024
Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md. Electronic address:
Background: Hypereosinophilic syndromes (HES) are defined as hypereosinophilia with eosinophil-related clinical manifestations, some of which overlap in presentation with asthma, atopic dermatitis, eosinophilic esophagitis, and/or chronic rhinosinusitis with nasal polyps. Dupilumab is approved to treat these conditions but can induce a transient rise in the absolute eosinophil count and rare eosinophil-related complications.
Objective: To determine whether eosinophil-related complications of dupilumab are increased in HES.
[Hypereosinophilic syndrome, case report and diagnostic approach].
Rev Med Inst Mex Seguro Soc
March 2024
Instituto Mexicano del Seguro Social, Hospital General de Zona No. 47 Vicente Guerrero, Servicio de Medicina Interna. Ciudad de México, México.
Article Synopsis
- - *Hypereosinophilic syndrome (HES) is a rare blood disorder that leads to high levels of eosinophils, which can cause damage to various tissues, often discovered incidentally due to its asymptomatic onset.* - *A clinical case involving a 69-year-old male with chronic conditions showed symptoms like skin lesions and blood abnormalities, leading to a diagnosis of idiopathic HES after further testing confirmed eosinophilic infiltration.* - *Eosinophilic disorders can have various clinical signs, especially skin-related issues, and are linked to chronic kidney disease; hence, early diagnosis and treatment are essential for better patient outcomes.*
Non-episodic angioedema with eosinophilia as a differential diagnosis of eosinophilia in young females.
World Allergy Organ J
November 2024
Department of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Article Synopsis
[Acute eosinophilic pneumonia presented with hemoptysis as the first manifestation].
Zhonghua Jie He He Hu Xi Za Zhi
November 2024
Departmment of Pulmonary and Critical Care Medicine, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China.
Article Synopsis
- A 38-year-old man was admitted with hemoptysis (coughing up blood) after increasing his tobacco use, and CT scans revealed multiple ground-glass opacities in his lungs.
- A bronchoalveolar lavage showed high levels of eosinophils, leading to a diagnosis of acute eosinophilic pneumonia (AEP).
- After starting corticosteroid therapy, a follow-up CT scan showed complete resolution of the opacities, highlighting that hemoptysis can be an atypical presentation of AEP, especially after tobacco exposure.
Multiple Cerebral Infarcts and Encephalopathy as the First Clinical Manifestations of Hypereosinophilic Syndrome: A Case Report and Narrative Review.
Pulse (Basel)
August 2024
Stroke Care, Neurology Operating Unit, Emergency-Urgency Department, University-Hospital of Parma, Parma, Italy.
Article Synopsis
- Hypereosinophilic syndrome is defined by elevated eosinophil levels in blood and/or bone marrow, often leading to organ damage and potentially neurological issues.
- A case study revealed that hypereosinophilia can cause Loeffler endocarditis, resulting in multiple strokes and encephalopathy as initial symptoms.
- This case emphasizes the need for clinicians to recognize hypereosinophilic syndrome as a possible cause of unusual stroke presentations, especially when neurological symptoms appear first.
Imatinib is effective in some PDGFRA/B-negative hypereosinophilic syndromes: A step closer to unveiling underlying mechanisms.
Br J Haematol
December 2024
Department of Hematology and Bone Marrow Transplantation, Faculty of Medicine in Katowice, Medical University of Silesia, Katowice, Poland.
Article Synopsis
- Hypereosinophilic syndromes (HES) are disorders marked by high eosinophil levels that can lead to organ damage.
- A study by Kim et al. treated 32 patients with PDGFRA/B-negative HES using imatinib, showing an overall response rate of 46.9% and a complete response rate of 18.8%, with effects seen in about 1.5 months.
- Genetic analysis revealed specific gene fusions correlating with treatment response, suggesting imatinib could be an effective option for certain patients with this syndrome.
Inflammatory profile of eosinophils in asthma-COPD overlap and eosinophilic COPD: a multi-omics study.
Front Immunol
October 2024
Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
Article Synopsis
- - Elevated blood eosinophil levels in COPD patients, particularly those with asthma-COPD overlap (ACO) and eosinophilic COPD (eCOPD), correlate with more frequent exacerbations and varying responses to inhaled corticosteroid treatments, due to unique inflammatory characteristics of eosinophils.
- - The study utilized a multi-omics approach to analyze eosinophils from patients, revealing that virus-related and inflammatory response markers, as well as disrupted cholesterol metabolism, play crucial roles in the pathology of ACO and eCOPD.
- - Findings suggest that treatments with atorvastatin, dexamethasone, and prostaglandin E2 (PGE2) can alter the inflammatory behavior of eos
AGA Clinical Practice Update on Esophageal Dysfunction Due to Disordered Immunity and Infection: Expert Review.
Clin Gastroenterol Hepatol
December 2024
Division of Gastroenterology, University of Utah, Salt Lake City, Utah. Electronic address:
Article Synopsis
- The American Gastroenterological Association (AGA) commissioned this expert review to provide guidance on diagnosing infectious and immune-mediated esophageal disorders, which are often under-recognized and lead to dysfunction and health costs.
- The review offers Best Practice Advice (BPA) statements based on published literature and expert opinions, but lacks formal evidence ratings due to the absence of systematic reviews.
- Increased awareness among gastroenterologists regarding these disorders can enhance patient care by improving diagnosis and limiting unnecessary medical procedures, particularly in patients presenting with dysphagia, heartburn, and odynophagia.
Mepolizumab-responsive recurrent eosinophilic eruption without peripheral eosinophilia.
JAAD Case Rep
November 2024
Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
A rare case of PDGFRA-positive chronic eosinophilic leukemia.
Indian J Pathol Microbiol
October 2024
Consultant Cardiologist, Salkars' Clinic Nagpur, Maharashtra, India.
Article Synopsis
- Chronic eosinophilic leukemia (CEL) is defined as an abnormal increase in eosinophils, which are a type of white blood cell, leading to potential tissue damage and affecting various organs.
- The clinical features of CEL can be similar to idiopathic hypereosinophilic syndrome (IHES), making diagnosis challenging.
- A case study presented a 49-year-old man with organ damage and blood tests revealing high eosinophil levels and some blasts, indicating a complex and rare manifestation of CEL compared to typical cases.
An Uncommon Cause of Acute Heart Failure: A Case Report.
Cureus
September 2024
Department of Cardiology, Unidade Local de Saúde de Almada-Seixal, Almada, PRT.
Article Synopsis
- - Hypereosinophilic syndromes (HES) are rare disorders that cause high levels of eosinophils in the blood, leading to potential damage to various organs, with the skin, lungs, heart, and gut being the most affected.
- - A 39-year-old woman experienced serious complications from HES, including heart failure and encephalopathy, after being admitted for a blood clot, and was diagnosed with idiopathic HES impacting multiple organs.
- - Although she initially responded well to high-dose corticosteroids, her failure to adhere to prescribed treatment ultimately led to disease progression and her death, emphasizing the critical need for consistent medical compliance in managing HES.
Eosinophilic myocarditis: a diagnostic challenge and treatment dilemma-a case report.
Eur Heart J Case Rep
October 2024
Department of Cardiology, Ibn Rochd University Hospital, Casablanca 20503, Morocco.
Article Synopsis
- Eosinophilic myocarditis is a rare and serious heart condition that can mimic acute coronary syndrome (ACS), creating challenges in diagnosis.
- A case involving a 32-year-old man with ACS-like symptoms, notable eosinophilia, and increased cardiac enzyme levels ultimately revealed eosinophilic myocarditis after non-invasive assessments, despite no biopsy.
- The report stresses the need for medical professionals to consider eosinophilic myocarditis in patients with chest pain and high eosinophil counts, as timely recognition and treatment can significantly improve patient outcomes.
Phase II trial of imatinib mesylate in patients with PDGFRA/B-negative hypereosinophilic syndrome.
Br J Haematol
December 2024
Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Article Synopsis
- A phase II clinical trial was conducted to assess the effectiveness of imatinib in treating PDGFRA/B-negative hypereosinophilic syndromes (HES), with 32 patients receiving doses ranging from 100-400 mg daily.
- The study found a haematological response rate of 46.9%, with 18.8% achieving a complete response, and the median time to this response was 1.5 months.
- Genetic analysis revealed that while there were no differences in non-silent mutations between responders and non-responders, specific gene fusions were linked to sustained responses, suggesting imatinib could be a viable treatment alongside proper biomarkers.
Biologics in Hypereosinophilic Syndrome and Eosinophilic Granulomatosis with Polyangiitis.
Immunol Allergy Clin North Am
November 2024
Human Eosinophil Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 4, Room B1-28, 4 Memorial Drive, Bethesda, MD 20892, USA. Electronic address:
Article Synopsis
- Hypereosinophilic syndrome (HES) and eosinophilic granulomatosis with polyangiitis (EGPA) are disorders characterized by high levels of eosinophils in the blood and tissues, leading to varied symptoms.
- Traditionally, treatment has relied on systemic glucocorticoids; however, new biologic therapies targeting eosinophils offer alternatives that could lead to better results with fewer side effects.
- The article reviews the evidence for using these biologics in treating HES and EGPA and outlines how they can be effectively employed in patient care.
Rapid identification of primary atopic disorders (PAD) by a clinical landmark-guided, upfront use of genomic sequencing.
Allergol Select
October 2024
Center for Child and Adolescent Health, Helios Hospital Krefeld, Academic Hospital of RWTH Aachen, Krefeld.
Article Synopsis
- Primary atopic disorders (PAD) are rare genetic conditions caused by specific gene variants that affect skin and immune function, making diagnosis challenging among common allergic disease cases.
- Identifying PAD requires recognizing clinical red flags like family history and unusual infections, as conventional lab tests are inadequate for definitive diagnosis.
- Whole-genome sequencing (WGS) enhances diagnostic efficiency and accuracy, but requires careful interpretation and collaboration among specialists to effectively manage PAD cases.
Severe Acute Respiratory Distress in a Child with Hypereosinophilic Syndrome: A Case Report.
JNMA J Nepal Med Assoc
April 2024
Department of Radiodiagnosis, B.P. Koirala Institute of Health Sciences, Dharan, Sunsari, Nepal.
Article Synopsis
- Hypereosinophilic syndrome is a rare condition in children that can cause respiratory distress and affect multiple organs, making accurate diagnosis crucial.
- Immediate treatment with corticosteroids is necessary to stabilize the patient and prevent further organ damage.
- A case study is presented of an adolescent male with severe eosinophilia affecting his lungs, heart, and abdomen, successfully treated with steroids and anthelmintics, emphasizing the need for prompt identification and management of the syndrome.